Stephen M. Ansell

TL;DR: Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma.

TL;DR: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after autologous stem-cell transplantation (auto-SCT).

TL;DR: It is shown that BCL2 mutations commonly occur in patients with BCL 2/IgH rearrangements as a result of somatic hypermutation normally occurring at the IgH locus, and an algorithm designed to identify likely functionally relevant but infrequent mutations is identified as likely drivers of DLBCL pathogenesis in some patients.

TL;DR: Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas and PD-L1/PD-L2 locus integrity and protein expression.

TL;DR: Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin, and might be a new treatment option for a patient population with a high unmet need.